A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

NCT02960854 PHASE1 COMPLETED Results posted

A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE1
Status	COMPLETED
Enrolment	38
Start date	Wed Dec 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Severe Sepsis

Interventions

• Nivolumab

Countries

United States